The collaboration combines the MaxCyte ExPERT platform (shown above) and Flow Electroporation technology with Ori’s next-generation cell therapy manufacturing platform, IRO. [MaxCyte]
MaxCyte and Ori Biotech entered into a strategic collaboration aimed at enhancing efficiency, scalability, and productivity in cell therapy manufacturing. The collaboration combines the MaxCyte ExPERT™ platform and Flow Electroporation® technology with Ori’s next-generation cell therapy manufacturing platform, IRO® (ee-RO).
The collaboration will specifically evaluate how the IRO platform can optimize the yield and streamline the manufacturing timelines of MaxCyte-engineered primary T cells compared to traditional post-electroporation cell expansion processes, according to officials at both companies. As a key component of this joint effort, Ori and MaxCyte have selected CD19 CAR expression via CRISPR knock-in in activated T cells as the test system for initial evaluation.
MaxCyte’s technology transfects cells at clinical scale, integrating with upstream and downstream processes within cell therapy workflows. The IRO platform complements this by introducing automated fluid handling and customizable mixing, and the OriConnect® tubeless sterile connection system was designed to enhance cell culture efficiency and scalability.
Together, these complementary technologies provide therapy developers with a powerful toolkit to achieve clinically relevant quantities of gene-edited T cells more rapidly and efficiently, notes Maher Masoud, president and CEO of MaxCyte.
“We are excited to collaborate with the team at Ori Biotech, combining our respective strengths and innovative technologies to significantly enhance manufacturing processes,” continues Masoud. “This partnership underscores our commitment to enabling therapy developers to more effectively address the evolving demands of cell therapy manufacturing, ultimately accelerating the availability of transformative treatments for patients.”
“Our partnership with MaxCyte is another example of Ori’s dedication to providing flexible and scalable solutions that address critical challenges in cell and gene therapy manufacturing,” adds Jason C. Foster, CEO of Ori Biotech. “By integrating modular, best-of-breed technologies, we’re raising the standard of manufacturing by enhancing commercial viability. Ultimately, this collaboration helps bring cell therapies to patients faster, more reliably, and at greater scale.”
